<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36952379</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>13</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Guam ALS-PDC is a distinct double-prion disorder featuring both tau and A&#x3b2; prions.</ArticleTitle><Pagination><StartPage>e2220984120</StartPage><MedlinePgn>e2220984120</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2220984120</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2220984120</ELocationID><Abstract><AbstractText>The amyotrophic lateral sclerosis-parkinsonism dementia complex (ALS-PDC) of Guam is an endemic neurodegenerative disease that features widespread tau tangles, occasional &#x3b1;-synuclein Lewy bodies, and sparse &#x3b2;-amyloid (A&#x3b2;) plaques distributed in the central nervous system. Extensive studies of genetic or environmental factors have failed to identify a cause of ALS-PDC. Building on prior work describing the detection of tau and A&#x3b2; prions in Alzheimer's disease (AD) and Down syndrome brains, we investigated ALS-PDC brain samples for the presence of prions. We obtained postmortem frozen brain tissue from 26 donors from Guam with ALS-PDC or no neurological impairment and 71 non-Guamanian donors with AD or no neurological impairment. We employed cellular bioassays to detect the prion conformers of tau, &#x3b1;-synuclein, and A&#x3b2; proteins in brain extracts. In ALS-PDC brain samples, we detected high titers of tau and A&#x3b2; prions, but we did not detect &#x3b1;-synuclein prions in either cohort. The specific activity of tau and A&#x3b2; prions was increased in Guam ALS-PDC compared with sporadic AD. Applying partial least squares regression to all biochemical and prion infectivity measurements, we demonstrated that the ALS-PDC cohort has a unique molecular signature distinguishable from AD. Our findings argue that Guam ALS-PDC is a distinct double-prion disorder featuring both tau and A&#x3b2; prions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Condello</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayers</LastName><ForeName>Jacob I</ForeName><Initials>JI</Initials><Identifier Source="ORCID">0000-0003-4544-2366</Identifier><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalgard</LastName><ForeName>Clifton L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Physiology, and Genetics, Uniformed Services University of the Health Sciences, F. Edward H&#xe9;bert School of Medicine, Bethesda, MD 20814.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD 20814.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia Garcia</LastName><ForeName>M Madhy</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-7053-0523</Identifier><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Brianna M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><Identifier Source="ORCID">0000-0003-1410-2027</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perl</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Uniformed Services University of the Health Sciences, F. Edward H&#xe9;bert School of Medicine, Bethesda, MD 20814.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prusiner</LastName><ForeName>Stanley B</ForeName><Initials>SB</Initials><Identifier Source="ORCID">0000-0003-1955-5498</Identifier><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG002132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="Y">Prions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="Y">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017096" MajorTopicYN="Y">Prion Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">Guam</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">prions</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>The authors have organizational affiliations to disclose: S.B.P. is the acting president of Prio-Pharma. The authors have stock ownership to disclose: J.I.A. and S.B.P. are shareholders in Prio-Pharma. The authors have patent filings to disclose: Ayers, Paras, and Prusiner, U.S. Application Serial No. 17/943,988 &#x201c;Assays for Classifying Alpha-Synuclein Prion Diseases.&#x201d; Paras, Merz, et&#xa0;al., U.S. Application Serial No. 63/247,230 &#x201c;Drugs for Neurodegenerative Diseases.&#x201d;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>13</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36952379</ArticleId><ArticleId IdType="pmc">PMC10068802</ArticleId><ArticleId IdType="doi">10.1073/pnas.2220984120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zimmerman H. M., Memorandum to U.S.N. medical research unit No. 2 (1945).</Citation></Reference><Reference><Citation>Arnold A., Edgren D. C., Palladino V. S., Amyotrophic lateral sclerosis; fifty cases observed on Guam. J. Nerv. Ment. Dis. 117, 135&#x2013;139 (1953).</Citation><ArticleIdList><ArticleId IdType="pubmed">13061952</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder D. W., Kurland L. T., Iriarte L. L., Neurologic diseases on the island of Guam. U.S. Armed Forces. Med. J. 5, 1724&#x2013;1739 (1954).</Citation><ArticleIdList><ArticleId IdType="pubmed">13217119</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurland L. T., et al. , Amyotrophic lateral sclerosis in the Mariana Islands. AMA Arch. Neurol. Psychiatry 75, 435&#x2013;441 (1956).</Citation><ArticleIdList><ArticleId IdType="pubmed">13301100</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A., Kurland L. T., Krooth R. S., Lessell S., Parkinsonism-dementia complex, an endemic disease on the island of Guam. I. Clinical features. Brain 84, 642&#x2013;661 (1961).</Citation><ArticleIdList><ArticleId IdType="pubmed">13907609</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed D. M., Brody J. A., Amyotrophic lateral sclerosis and parkinsonism-dementia on Guam, 1945&#x2013;1972. I. Descriptive epidemiology. Am. J. Epidemiol. 101, 287&#x2013;301 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1124759</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A., Malamud N., Kurland L. T., Parkinsonism-dementia complex, an endemic disease on the island of Guam. II. Pathological features. Brain 84, 662&#x2013;679 (1961).</Citation><ArticleIdList><ArticleId IdType="pubmed">13907610</ArticleId></ArticleIdList></Reference><Reference><Citation>Malamud N., Hirano A., Kurland L. T., Pathoanatomic changes in amyotrophic lateral sclerosis on Guam. Special reference to the occurrence of neurofibrillary changes. Arch. Neurol. 5, 401&#x2013;415 (1961).</Citation><ArticleIdList><ArticleId IdType="pubmed">14468803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A., Arumugasamy N., Zimmerman H. M., Amyotrophic lateral sclerosis. A comparison of Guam and classical cases. Arch. Neurol. 16, 357&#x2013;363 (1967).</Citation><ArticleIdList><ArticleId IdType="pubmed">6021482</ArticleId></ArticleIdList></Reference><Reference><Citation>Garruto R. M., Gajdusek D. C., Chen K. M., Amyotrophic lateral sclerosis and parkinsonism-dementia among Filipino migrants to Guam. Ann. Neurol. 10, 341&#x2013;350 (1981).</Citation><ArticleIdList><ArticleId IdType="pubmed">7316487</ArticleId></ArticleIdList></Reference><Reference><Citation>Plato C. C., et al. , Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: Changing incidence rates during the past 60 years. Am. J. Epidemiol. 157, 149&#x2013;157 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12522022</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof P. R., et al. , Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam: Quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders. Acta Neuropathol. 88, 397&#x2013;404 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7847067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e-Scherrer V., et al. , Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins. Am J Pathol. 146, 924&#x2013;932 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1869250</ArticleId><ArticleId IdType="pubmed">7717459</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawal-Dewan M., et al. , Identification of phosphorylation sites in PHF-TAU from patients with Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex. J. Neuropathol. Exp. Neurol. 55, 1051&#x2013;1059 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8858002</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyanagi K., et al. , Distinct pathological features of the gallyas- and tau-positive glia in the parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. J. Neuropathol. Exp. Neurol. 56, 308&#x2013;316 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9056545</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki M., et al. , Tau-positive fine granules in the cerebral white matter: A novel finding among the tauopathies exclusive to parkinsonism-dementia complex of Guam. J. Neuropathol. Exp. Neurol. 64, 839&#x2013;846 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16215455</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton M. J., et al. , Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex. Acta Neuropathol. 111, 401&#x2013;412 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16609851</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki M., et al. , &#x3b1;-Synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J. Neuropathol. Exp. Neurol. 59, 585&#x2013;591 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10901229</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman M. S., et al. , Tau and &#x3b1;-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. Am. J. Pathol. 160, 1725&#x2013;1731 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850878</ArticleId><ArticleId IdType="pubmed">12000724</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebeo J., Hof P. R., Perl D. P., Occurrence of &#x3b1;-synuclein pathology in the cerebellum of Guamanian patients with parkinsonism-dementia complex. Acta Neuropathol. 107, 497&#x2013;503 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15024581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof P. R., Perl D. P., Loerzel A. J., Morrison J. H., Neurofibrillary tangle distribution in the cerebral cortex of parkinsonism-dementia cases from Guam: Differences with Alzheimer&#x2019;s disease. Brain Res. 564, 306&#x2013;313 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1810629</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C., Steele J. C., Akiyama H., McGeer P. L., Distinct distribution of apolipoprotein E and &#x3b2;-amyloid immunoreactivity in the hippocampus of Parkinson dementia complex of Guam. Acta Neuropathol. 92, 378&#x2013;385 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8891070</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M. L., et al. , Amyloid plaques in Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex contain species of A&#x3b2; similar to those found in the amyloid plaques of Alzheimer&#x2019;s disease and pathological aging. Acta Neuropathol. 95, 117&#x2013;122 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9498044</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentleman S. M., et al. , &#x3b2;(A4)-amyloid protein and parkinsonian dementia complex of Guam. Lancet 337, 55&#x2013;56 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1670679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H., Hirano H., Yen S. H., Kato S., Demonstration of &#x3b2; amyloid protein-containing neurofibrillary tangles in parkinsonism-dementia complex on Guam. Neuropathol. Appl. Neurobiol. 17, 365&#x2013;373 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1758569</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiroy D. C., et al. , Neurofibrillary tangles of Guamanian amyotrophic lateral sclerosis, parkinsonism-dementia and neurologically normal Guamanians contain a 4- to 4.5-kilodalton protein which is immunoreactive to anti-amyloid &#x3b2;/A4-protein antibodies. Acta Neuropathol. 86, 265&#x2013;274 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8213085</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C., Steele J. C., Akiyama H., McGeer E. G., McGeer P. L., Relationship of amyloid &#x3b2;/A4 protein to the neurofibrillary tangles in Guamanian parkinsonism-dementia. Acta Neuropathol. 90, 287&#x2013;298 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8525803</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner S. B., Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336, 1511&#x2013;1513 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942086</ArticleId><ArticleId IdType="pubmed">22723400</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner S. B., Some speculations about prions, amyloid, and Alzheimer&#x2019;s disease. N. Engl. J. Med. 310, 661&#x2013;663 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6363926</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M., et al. , Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313, 1781&#x2013;1784 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F., et al. , Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909&#x2013;913 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts J. C., et al. , Serial propagation of distinct strains of A&#x3b2; prions from Alzheimer&#x2019;s disease patients. Proc. Natl. Acad. Sci. U.S.A. 111, 10323&#x2013;10328 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104857</ArticleId><ArticleId IdType="pubmed">24982139</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner S. B., et al. , Evidence for &#x3b1;-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 112, E5308&#x2013;E5317 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586853</ArticleId><ArticleId IdType="pubmed">26324905</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A., Malamud N., Elizan T. S., Kurland L. T., Amyotrophic lateral sclerosis and Parkinsonism-dementia complex on Guam. Further pathologic studies. Arch. Neurol. 15, 35&#x2013;51 (1966).</Citation><ArticleIdList><ArticleId IdType="pubmed">5939450</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs C. J. Jr., Gajdusek D. C., Amyotrophic lateral sclerosis, Parkinson's disease, and the amyotrophic lateral sclerosis-Parkinsonism-dementia complex on Guam: A review and summary of attempts to demonstrate infection as the aetiology. J. Clin. Pathol. Suppl. (R. Coll. Pathol.) 6, 132&#x2013;140 (1972).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347262</ArticleId><ArticleId IdType="pubmed">4218241</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs C. J. Jr., Gajdusek D. C., An update on long-term in vivo and in vitro studies designed to identify a virus as the cause of amyotrophic lateral sclerosis, parkinsonism dementia, and Parkinson&#x2019;s disease. Adv. Neurol. 36, 343&#x2013;353 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">6817614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders D. W., et al. , Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman A. L., et al. , Propagation of prions causing synucleinopathies in cultured cells. Proc. Natl. Acad. Sci. U.S.A. 112, E4949&#x2013;E4958 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4568231</ArticleId><ArticleId IdType="pubmed">26286986</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman A. L., et al. , Tau prions from Alzheimer&#x2019;s disease and chronic traumatic encephalopathy patients propagate in cultured cells. Proc. Natl. Acad. Sci. U.S.A. 113, E8187&#x2013;E8196 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5167200</ArticleId><ArticleId IdType="pubmed">27911827</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi A., et al. , A&#x3b2; and tau prion-like activities decline with longevity in the Alzheimer&#x2019;s disease human brain. Sci. Transl. Med. 11, eaat8462 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640844</ArticleId><ArticleId IdType="pubmed">31043574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers J. I., et al. , Different &#x3b1;-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. Proc. Natl. Acad. Sci. U.S.A. 119, e2113489119 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8833220</ArticleId><ArticleId IdType="pubmed">35115402</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C., et al. , A&#x3b2; and tau prions feature in the neuropathogenesis of Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 119, e2212954119 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9674250</ArticleId><ArticleId IdType="pubmed">36343257</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson N. R., et al. , Evidence for sortilin modulating regional accumulation of human tau prions in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 114, E11029&#x2013;E11036 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754811</ArticleId><ArticleId IdType="pubmed">29203673</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson F. H., Richardson E. P. Jr., Okazaki H., Brody J. A., Neurofibrillary degeneration on Guam: frequency in Chamorros and non Chamorros with no known neurological disease. Brain 102, 65&#x2013;77 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">427533</ArticleId></ArticleIdList></Reference><Reference><Citation>Perl D. P., Hof P. R., Purohit D. P., Loerzel A. J., Kakulas B. A., Hippocampal and entorhinal cortex neurofibrillary tangle formation in Guamanian Chamorros free of overt neurologic dysfunction. J. Neuropathol. Exp. Neurol. 62, 381&#x2013;388 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12722830</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris H. R., et al. , Genome-wide analysis of the parkinsonism-dementia complex of Guam. Arch. Neurol. 61, 1889&#x2013;1897 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15596609</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman J. L., et al. , Widespread tau seeding activity at early Braak stages. Acta Neuropathol. 133, 91&#x2013;100 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833300</ArticleId><ArticleId IdType="pubmed">27878366</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman A. L., et al. , Kinetics of human mutant tau prion formation in the brains of two transgenic mouse lines. JAMA Neurol. 74, 1464&#x2013;1472 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822201</ArticleId><ArticleId IdType="pubmed">29059326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L., et al. , A&#x3b2; seeding potency peaks in the early stages of cerebral &#x3b2;-amyloidosis. EMBO Rep. 18, 1536&#x2013;1544 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5579388</ArticleId><ArticleId IdType="pubmed">28701326</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman A. L., et al. , Kinetics of &#x3b1;-synuclein prions preceding neuropathological inclusions in multiple system atrophy. PLOS Pathog. 16, e1008222 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6999861</ArticleId><ArticleId IdType="pubmed">32017806</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C., McGeer P. L., A&#x3b2;42-carboxy-terminal-like immunoreactivity is associated with intracellular neurofibrillary tangles and pick bodies. Exp. Neurol. 161, 527&#x2013;534 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10686074</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori C., et al. , Intraneuronal A&#x3b2;42 accumulation in Down syndrome brain. Amyloid 9, 88&#x2013;102 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12440481</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo A. M., et al. , A&#x3b2; localization in abnormal endosomes: Association with earliest A&#x3b2; elevations in AD and Down syndrome. Neurobiol. Aging. 25, 1263&#x2013;1272 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15465622</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker-Nigh A., et al. , Neuronal amyloid-&#x3b2; accumulation within cholinergic basal forebrain in ageing and Alzheimer&#x2019;s disease. Brain 138, 1722&#x2013;1737 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542619</ArticleId><ArticleId IdType="pubmed">25732182</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C., et al. , Structural heterogeneity and intersubject variability of A&#x3b2; in familial and sporadic Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U.S.A. 115, E782&#x2013;E791 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5789926</ArticleId><ArticleId IdType="pubmed">29311311</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarathinam A., et al. , Membrane-anchored A&#x3b2; accelerates amyloid formation and exacerbates amyloid-associated toxicity in mice. J. Neurosci. 33, 19284&#x2013;19294 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618790</ArticleId><ArticleId IdType="pubmed">24305824</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzesco A.-M., et al. , Highly potent intracellular membrane-associated A&#x3b2; seeds. Sci. Rep. 6, 28125 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4911570</ArticleId><ArticleId IdType="pubmed">27311744</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinerman J. R., et al. , Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch. Neurol. 65, 906&#x2013;912 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586606</ArticleId><ArticleId IdType="pubmed">18625856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs G. G., Robinson J. L., Perl D. P., Lee V. M., Trojanowski J. Q., Thorn-shaped astrocytes in the depth of cortical sulci in Western Pacific ALS/Parkinsonism-Dementia complex. Acta Neuropathol. 140, 591&#x2013;593 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7986993</ArticleId><ArticleId IdType="pubmed">32662040</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung D. C., et al. , Tau exhibits unique seeding properties in globular glial tauopathy. Acta Neuropathol. Commun. 7, 36 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6404306</ArticleId><ArticleId IdType="pubmed">30845985</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., et al. , TDP-43 is deposited in the Guam parkinsonism&#x2013;dementia complex brains. Brain 130, 1386&#x2013;1394 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17439983</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F., et al. , Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol. 115, 133&#x2013;145 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17713769</ArticleId></ArticleIdList></Reference><Reference><Citation>Miklossy J., et al. , Enduring involvement of tau, &#x3b2;-amyloid, &#x3b1;-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism&#x2013;dementia complex of Guam (ALS/PDC). Acta Neuropathol. 116, 625&#x2013;637 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18843496</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T., Frosch M. P., Lesions without symptoms: Understanding resilience to Alzheimer disease neuropathological changes. Nat. Rev. Neurol. 18, 323&#x2013;332 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35332316</ArticleId></ArticleIdList></Reference><Reference><Citation>Duran-Aniotz C., Morales R., Moreno-Gonzalez I., Hu P. P., Soto C., Brains from non-Alzheimer&#x2019;s individuals containing amyloid deposits accelerate A&#x3b2; deposition in vivo. Acta Neuropathol. Commun. 1, 76 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046659</ArticleId><ArticleId IdType="pubmed">24252208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakayama I., Kihira T., Yoshida S., Garruto R. M., Rare neuropil threads in amyotrophic lateral sclerosis and parkinsonism-dementia on Guam and in the Kii Peninsula of Japan. Dementia 4, 75&#x2013;80 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8358516</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh N., et al. , Biochemical and ultrastructural study of neurofibrillary tangles in amyotrophic lateral sclerosis/parkinsonism-dementia complex in the Kii peninsula of Japan. J. Neuropathol. Exp. Neurol. 62, 791&#x2013;798 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12901704</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzuhara S., Kokubo Y., Atypical parkinsonism of Japan: Amyotrophic lateral sclerosis-parkinsonism-dementia complex of the Kii peninsula of Japan (Muro disease): An update. Mov. Disord. 20, S108&#x2013;S113 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16092099</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimuro M., Yoshida M., Kuzuhara S., Kokubo Y., Amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Hohara focus of the Kii Peninsula: A multiple proteinopathy? Neuropathology 38, 98&#x2013;107 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29063640</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajdusek D. C., Salazar A. M., Amyotrophic lateral sclerosis and parkinsonian syndromes in high incidence among the Auyu and Jakai people of West New Guinea. Neurology 32, 107&#x2013;126 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7198738</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumiya K., et al. , Amyotrophic lateral sclerosis and parkinsonism in Papua, Indonesia: 2001&#x2013;2012 survey results. BMJ Open 4, e004353 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3996815</ArticleId><ArticleId IdType="pubmed">24740977</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannuzel A., et al. , Clinical varieties and epidemiological aspects of amyotrophic lateral sclerosis in the Caribbean island of Guadeloupe: A new focus of ALS associated with Parkinsonism. Amyotroph. Lateral Scler. Frontotemporal Degener. 16, 216&#x2013;223 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25646866</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauwendraat C., et al. , NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol. Aging. 57, 247.e9&#x2013;247.e13 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5534378</ArticleId><ArticleId IdType="pubmed">28602509</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine D. J., et al. , Mechanism of scrapie prion precipitation with phosphotungstate anions. ACS Chem. Biol. 10, 1269&#x2013;1277 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437617</ArticleId><ArticleId IdType="pubmed">25695325</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdi H., Partial least squares regression and projection on latent structure regression (PLS Regression). Wiley Interdiscip. Rev. Comput. Stat. 2, 97&#x2013;106 (2010).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>